The research underscores the crucial function of non-coding RNAs in gene regulation, especially in the context of cancer development. Unlike conventional protein-coding genes, non-coding RNAs do not translate into proteins but play vital roles in regulating gene expression at transcriptional and post-transcriptional levels. The manipulation of such molecules within the microenvironment of leukemias can engender profound changes in tumor behavior and therapeutic response.

EVs emerge as crucial carriers of these non-coding RNAs, providing a vehicle through which cells communicate and modulate their phenotypic characteristics. The vesicles are shed from various cell types, including tumor cells, and can be detected in bodily fluids such as blood and urine. This makes them tantalizing candidates for liquid biopsy applications, offering a non-invasive method for cancer detection and monitoring, with implications for patient management.

The authors reviewed numerous studies that investigated the content of EVs derived from leukemic cells. It has been observed that these vesicles can encapsulate various RNA species, including microRNAs and long non-coding RNAs, which can influence the behavior of both the tumor and surrounding stromal cells. For instance, specific microRNAs released from leukemic cells have been shown to foster a tumor-promoting microenvironment by affecting immune cell functions and enhancing angiogenesis, thereby facilitating tumor progression.

In pre-leukemic syndromes, the role of extracellular vesicle-derived ncRNAs might be critical in the early stages of disease progression. The evidence suggests that these molecules can serve as early biomarkers for predicting the transition from pre-leukemic conditions to full-blown leukemia. By understanding the ncRNA profiles found within EVs, researchers hope to identify potential therapeutic targets or even therapeutic agents that could ameliorate disease severity or progression.

One of the most promising aspects of this research is the therapeutic potential of targeting EVs themselves. Since these vesicles can mediate the delivery of anti-cancer agents or RNA-based therapeutics, manipulating their release or content might represent a novel approach to treating leukemias and their precursors. Innovative techniques such as RNA interference and CRISPR-based gene editing could be employed to modify the molecular content of EVs, which may enhance their efficacy as therapeutic vehicles.

Moreover, the potential to exploit these vesicles for both diagnostic and therapeutic approaches underscores the necessity for further research in this domain. It is imperative to expand our understanding of the biogenesis, secretion, and uptake pathways of EVs, as well as their interaction with various cell types within the hematological environment. Such knowledge will be essential for harnessing the full potential of EVs in clinical applications.

The review also highlights the need for standardized methodologies for isolating and characterizing extracellular vesicles to enable comparability among studies. Currently, the field faces challenges related to the heterogeneity of EV populations, which might complicate the interpretation of findings across different research efforts. Establishing universal standards will facilitate a clearer understanding of EV dynamics in leukemia and enhance collaborative efforts in this rapidly evolving field.

As the body of evidence supporting the role of extracellular vesicles in cancer biology grows, the medical community is urged to consider their therapeutic implications. The findings discussed by Seddighi et al. could inspire novel strategies in the combat against leukemia. By focusing on the ncRNA content of EVs, there is potential to uncover novel biomarkers for early intervention or innovative treatment modalities.

In conclusion, the comprehensive review by Seddighi and colleagues positions extracellular vesicle-derived non-coding RNAs as a promising frontier in leukemia research. The findings advocate for more robust investigations to explore the biological underpinnings that govern these systems. The hope is that, with further elucidation of these complex interactions, clinical applications rooted in the manipulation of EVs can be realized, heralding a new age in the management of leukemias and related disorders.

This systematic review not only consolidates current knowledge but also lays a foundation for future experimental designs and clinical trials targeting the intricacies of extracellular vesicle biology in leukemia. It calls for increased collaboration across disciplines to harness the potential of these tiny but powerful molecular messengers for significant advancements in treatment strategies.

Subject of Research: The role of extracellular vesicle-derived non-coding RNAs in leukemias and pre-leukemic syndromes.

Article Title: Extracellular vesicles-derived non-coding RNA in leukemias and pre-leukemic syndromes: a systematic review.

Article References:

Seddighi, N., Najafpour, M., Riyahi, M. et al. Extracellular vesicles-derived non-coding RNA in leukemias and pre-leukemic syndromes: a systematic review.
J Cancer Res Clin Oncol 152, 20 (2026). https://doi.org/10.1007/s00432-025-06385-6

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00432-025-06385-6

Keywords: Non-coding RNA, extracellular vesicles, leukemia, biomarkers, cancer therapy, intercellular communication.

Oxaliplatin has long been a frontline weapon in combating colorectal cancer and various other malignancies. Despite its efficacy, resistance to oxaliplatin remains a formidable barrier, often leading to treatment failure and disease progression. Understanding the molecular underpinnings of this resistance is paramount for improving clinical outcomes. Tajik and Ghafouri-Fard’s investigation delineates how circRNAs intricately regulate cellular pathways that govern oxaliplatin sensitivity, charting new territories in cancer therapeutics.

CircRNAs are distinctive in their covalently closed loop structures, which confer exceptional stability compared to linear RNAs. This unique topology protects them from exonuclease-mediated degradation, allowing them to accumulate and exert sustained regulatory effects. The researchers delve into how this stability enables circRNAs to sponge microRNAs (miRNAs), interact with RNA binding proteins, and modulate transcriptional and post-transcriptional landscapes, ultimately influencing how cancer cells respond to chemotherapy.

One of the pivotal revelations from the study lies in the identification of specific circRNAs that act as molecular switches toggling oxaliplatin resistance. These circRNAs function predominantly as competing endogenous RNAs (ceRNAs) by sequestering miRNAs that would otherwise inhibit key oncogenes or drug resistance-associated genes. For instance, the circRNA-mediated sponging of tumor-suppressive miRNAs can alleviate repression on DNA repair genes, thus facilitating cancer cell survival during oxaliplatin-induced DNA damage.

Furthermore, the authors illuminate the bidirectional relationship between circRNAs and signaling pathways implicated in drug resistance. CircRNAs have been shown to modulate pathways such as Wnt/β-catenin, PI3K/Akt, and NF-κB, which confer survival advantages and attenuate apoptotic responses under chemotherapeutic stress. By fine-tuning these signaling cascades, circRNAs sculpt cellular landscapes that favor resistance phenotypes.

Importantly, the study underscores that circRNAs are not mere bystanders but active participants in the epigenetic remodeling that accompanies oxaliplatin resistance. They contribute to the reprogramming of chromatin states and transcriptional machinery through interactions with chromatin modifiers and transcription factors, thereby promoting gene expression patterns that support drug tolerance.

The therapeutic implications are profound. Targeting circRNAs or their interaction networks could restore oxaliplatin sensitivity and circumvent resistance. The study discusses innovative strategies like antisense oligonucleotides (ASOs) and CRISPR/Cas-mediated approaches that selectively degrade or alter circRNAs, offering precision intervention points. Additionally, circRNAs themselves may serve as prognostic biomarkers to predict patient responsiveness to oxaliplatin-based treatment regimens, enabling personalized medicine.

Intriguingly, circRNAs also modulate immune responses within the tumor microenvironment, which can indirectly influence chemotherapy efficacy. By regulating immune checkpoints and cytokine milieus, circRNAs may dictate the balance between immune surveillance and evasion, thus intersecting with immunotherapeutic strategies.

This research opens new avenues for combinatorial therapies. By integrating circRNA-targeting modalities with conventional oxaliplatin chemotherapy or emerging immunotherapies, clinicians may surmount resistance barriers, leading to more durable remissions. The exploitation of circRNA pathways offers a dual advantage: enhancing drug efficacy while minimizing off-target toxicities through specific molecular targeting.

Nevertheless, challenges persist in translating these molecular insights into clinical practice. The complexity of circRNA expression profiles across tumor types, heterogeneity among patients, and the dynamic nature of RNA interactions necessitate comprehensive profiling and longitudinal studies. Moreover, efficient delivery systems for circRNA-targeted therapeutics remain a crucial area for technological advancement.

Despite these hurdles, the revelation of circRNAs as master regulators of oxaliplatin response embodies a paradigm shift. It underscores the necessity of exploring non-coding RNA territories to unravel resistance mechanisms that have remained elusive for decades. The fundamental knowledge garnered not only deepens our understanding of cancer biology but also propels the development of next-generation therapeutics with the potential to redefine cancer treatment landscapes.

From a broader perspective, the study exemplifies the evolving narrative of precision oncology, where molecular intricacies guide tailored treatment decisions. CircRNAs offer a tantalizing glimpse into the molecular dark matter of the genome, turning what was once considered “junk” RNA into a treasure trove of therapeutic targets.

Future investigations will likely focus on expanding the catalog of circRNAs involved in drug resistance, unraveling their tissue-specific roles, and elucidating their interactions within larger regulatory networks. High-throughput sequencing combined with sophisticated bioinformatics will accelerate discoveries, while functional validation in preclinical models will pave the way for clinical translation.

In conclusion, Tajik and Ghafouri-Fard’s seminal work affirms the critical regulatory capacity of circRNAs in oxaliplatin response and resistance, positioning these non-coding RNAs at the forefront of cancer research and therapy innovation. As the fight against chemoresistant cancers intensifies, circRNAs stand out as promising allies, offering hope for more effective, personalized, and durable treatment outcomes.

Subject of Research: Circular RNAs as regulators of oxaliplatin response and resistance in cancer therapy

Article Title: Circular RNAs: emerging regulators of oxaliplatin response and resistance in cancer therapy

Article References:

Tajik, Z., Ghafouri-Fard, S. Circular RNAs: emerging regulators of oxaliplatin response and resistance in cancer therapy.
Med Oncol 43, 38 (2026). https://doi.org/10.1007/s12032-025-03171-9

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03171-9